Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2023 | $15.00 | Mkt Outperform | JMP Securities |
| 9/12/2023 | $26.00 | Buy | BTIG Research |
| 7/31/2023 | $29.00 | Outperform | RBC Capital Mkts |
| 6/14/2023 | $26.00 | Buy | B. Riley Securities |
| 6/2/2023 | $30.00 | Outperform | Oppenheimer |
| 5/19/2023 | $25.00 | Overweight | Cantor Fitzgerald |
| 4/7/2022 | $16.00 | Outperform | Robert W. Baird |
| 2/28/2022 | $6.00 | Neutral | Goldman Sachs |
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who